Twist Bioscience Corporation $TWST Shares Bought by AQR Capital Management LLC

Key Points

• AQR Capital Management LLC increased its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 65.2%, owning 265,649 shares after acquiring an additional 104,875 shares in the first quarter.
• Twist Bioscience has received a consensus rating of "Moderate Buy" from analysts with an average price target of $49.40.
• CFO Adam Laponis and CEO Emily M. Leproust recently sold shares of the company's stock, indicating insider selling activity amidst ongoing management transactions.

AQR Capital Management LLC boosted its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 65.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 265,649 shares of the company's stock after purchasing an additional 104,875 shares during the period. AQR Capital Management LLC owned about 0.44% of Twist Bioscience worth $10,429,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Nuveen LLC purchased a new stake in shares of Twist Bioscience in the first quarter worth about $31,960,000. ARK Investment Management LLC grew its stake in shares of Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock worth $245,045,000 after purchasing an additional 645,730 shares during the period. Citigroup Inc. increased its holdings in shares of Twist Bioscience by 124.1% during the 1st quarter. Citigroup Inc. now owns 206,461 shares of the company's stock valued at $8,106,000 after purchasing an additional 114,338 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Twist Bioscience in the 1st quarter valued at $3,977,000. Finally, Russell Investments Group Ltd. boosted its holdings in Twist Bioscience by 1,121.3% during the first quarter. Russell Investments Group Ltd. now owns 108,834 shares of the company's stock worth $4,273,000 after buying an additional 99,923 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TWST. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a report on Monday, August 4th. Cowen restated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Price Performance

Shares of NASDAQ TWST traded up $1.36 during trading on Tuesday, hitting $27.08. The company had a trading volume of 2,312,914 shares, compared to its average volume of 1,322,669. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -18.68 and a beta of 2.31. The stock has a fifty day simple moving average of $30.12 and a two-hundred day simple moving average of $34.04. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a fifty-two week low of $24.07 and a fifty-two week high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The firm had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other news, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the sale, the chief financial officer directly owned 103,569 shares of the company's stock, valued at $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 2,265 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $25.76, for a total value of $58,346.40. Following the completion of the transaction, the chief executive officer directly owned 634,740 shares of the company's stock, valued at approximately $16,350,902.40. This represents a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,911 shares of company stock worth $288,159. Company insiders own 3.01% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.